{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:00:02Z","timestamp":1790805602351,"version":"4.1.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T00:00:00Z","timestamp":1545177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Although classical Hodgkin lymphoma (cHL) is highly curable, 20%\u201330% of patients will not be cured with conventional treatments. The programmed death-1 (PD-1) inhibitors (PD-1i) nivolumab and pembrolizumab have been Food and Drug Administration-approved for relapsed\/refractory (R\/R) cHL. There is limited data on the real-world experience with PD-1i in cHL and it is unknown whether fewer selected patients treated with PD-1i derive benefits similar to those observed in published trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We performed a multicenter, retrospective analysis of R\/R cHL patients treated with PD-1i in the nontrial setting. The primary objective was to describe progression-free survival (PFS) and overall survival (OS) in this population. Secondary objectives were to characterize response rates, toxicities, discontinuation patterns, and post-PD-1i therapies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The study included 53 patients from nine U.S. centers. Overall response rate (ORR), complete response (CR), and partial response (PR) to PD-1i were 68%, 45%, and 23%, respectively. Twelve-month OS and PFS were 89% and 75%, respectively; median PFS was 29 months. Ninety-six percent of patients with CR continue to respond at a median follow-up of 20 months. Toxicities were similar to those previously described. Seventy percent of patients treated with systemic therapy after PD-1i demonstrated objective responses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>To our knowledge, this analysis is the first describing real-world experience with PD-1i in cHL patients in the U.S. Here, we demonstrate similar response rates compared to prior studies. The toxicity profile of PD-1i was similar to that seen in previous studies; we further describe toxicity patterns in those with prior autoimmune disease or allogeneic transplant. Post-PD-1i systemic therapies appear active. These results support the effectiveness and tolerability of PD-1i therapy in R\/R cHL in a real-world setting.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0538","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T21:04:23Z","timestamp":1545253463000},"page":"955-962","source":"Crossref","is-referenced-by-count":38,"title":["Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis"],"prefix":"10.1093","volume":"24","author":[{"given":"Steven M.","family":"Bair","sequence":"first","affiliation":[{"name":"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Strelec","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana A.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Hackensack Medical Center, Hackensack, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulrayz","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun N.","family":"Singavi","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Milwaukee, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishitha","family":"Reddy","sequence":"additional","affiliation":[{"name":"Vanderbilt University, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Khan","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalambos","family":"Andreadis","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khoan","family":"Vu","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott F.","family":"Huntington","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smith","family":"Giri","sequence":"additional","affiliation":[{"name":"Yale University, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitra","family":"Ujjani","sequence":"additional","affiliation":[{"name":"Georgetown University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Howlett","sequence":"additional","affiliation":[{"name":"Hackensack Medical Center, Hackensack, New Jersey, USA"},{"name":"Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik","family":"Faheem","sequence":"additional","affiliation":[{"name":"Hackensack Medical Center, Hackensack, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Youngman","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita D.","family":"Nasta","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Landsburg","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[{"name":"Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,12,19]]},"reference":[{"key":"2021122507241063600_R1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"2021122507241063600_R2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122507241063600_R3","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial ofabvdversus stanfordvwith or without radiation therapy in locally extensive and advanced-stage hodgkin lymphoma: An intergroup study coordinated by the eastern cooperative oncology group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021122507241063600_R4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.clml.2018.03.012","article-title":"Immunotherapy for the treatment of Hodgkin lymphoma: An evolving paradigm","volume":"18","author":"Bair","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2021122507241063600_R5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.6004\/jnccn.2015.0076","article-title":"Biologic agents in the management of Hodgkin lymphoma","volume":"13","author":"Rashidi","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122507241063600_R6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11864-016-0401-9","article-title":"checkpoint inhibitors and other immune therapies for Hodgkin and non-Hodgkin lymphoma","volume":"17","author":"Matsuki","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"2021122507241063600_R7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122507241063600_R8","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021122507241063600_R9","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021122507241063600_R10","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: Extended follow-up of the multicohort single-arm Phase II CheckMate 205 Trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2021122507241063600_R11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/hon.2437_124","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma after autologous transplant: Full results after extended follow-up of the phase 2 Checkmate 205 Trial","volume":"35","author":"Fanale","year":"2017","journal-title":"Hematol Oncol"},{"key":"2021122507241063600_R12","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood.V128.22.1110.1110","article-title":"Checkmate 205 update with minimum 12-month follow up: A phase 2 study of nivolumab in patients with relapsed\/refractory classical Hodgkin lymphoma","volume":"128","author":"Timmerman","year":"2016","journal-title":"Blood"},{"key":"2021122507241063600_R13","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021122507241063600_R14","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ajh.24792","article-title":"Outcomes in patients with relapsed\/refractory Hodgkin lymphoma progressi after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis","volume":"92","author":"Bair","year":"2017","journal-title":"Am J Hematol"},{"key":"2021122507241063600_R15","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122507241063600_R16","doi-asserted-by":"crossref","first-page":"1108a","DOI":"10.1182\/blood.V128.22.1108.1108","article-title":"Pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: Long-term efficacy from the Phase 1b Keynote-013 study","volume":"128","author":"Armand","year":"2016","journal-title":"Blood"},{"issue":"suppl 2","key":"2021122507241063600_R17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/hon.2437_125","article-title":"Pembrolizumab monotherapy in patients with primary refractory classical Hodgkin lymphoma: Subgroup analysis of the phase 2 Keynote-087 study","volume":"35","author":"Zinzani","year":"2017","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"2021122507241063600_R18","doi-asserted-by":"crossref","first-page":"650a","DOI":"10.1182\/blood.V130.Suppl_1.650.650","article-title":"Nivolumab treatment beyond investigator-assessed progression: Outcomes in patients with relapsed\/refractory classical Hodgkin lymphoma from the phase 2 Checkmate 205 study","volume":"130","author":"Cohen","year":"2017","journal-title":"Blood"},{"key":"2021122507241063600_R19","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021122507241063600_R20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2018-02-811174","article-title":"Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: Taming a necessary evil","volume":"132","author":"Herbaux","year":"2018","journal-title":"Blood"},{"key":"2021122507241063600_R21","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122507241063600_R22","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0538","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0538","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/7\/955\/41917732\/oncolo_24_7_955.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/7\/955\/41917732\/oncolo_24_7_955.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:25:42Z","timestamp":1640417142000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/7\/955\/6439383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,19]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,12,19]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0538","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7,1]]},"published":{"date-parts":[[2018,12,19]]}}}